C-Reactive Protein and Glycemic Control in Adult with Type 2 Diabetes Mellitus by Nanubala, Siva Krishna
 C-REACTIVE PROTEIN AND GLYCEMIC CONTROL IN ADULTS 
WITH TYPE 2 DIABETES MELLITUS 
 
 
Dissertation submitted to 
 
THE TAMIL NADU DR. M.G.R MEDICAL UNIVERSITY, CHENNAI 
 
In fulfilment of the regulations for the award of the degree of 
 
Doctor of Medicine in General Medicine 
 
 
 
 
 
 
DEPARTMENT OF GENERAL MEDICINE 
 
P.S.G INSTITUTE OF MEDICAL SCIENCES & RESEARCH 
 
THE TAMIL NADU DR. M.G.R MEDICAL UNIVERSITY, 
 
CHENNAI, TAMIL NADU 
 
 
 
APRIL 2016 
 C-REACTIVE PROTEIN AND GLYCEMIC CONTROL IN ADULTS 
WITH TYPE 2 DIABETES MELLITUS 
 
Dissertation submitted to 
 
The Tamil Nadu Dr. M.G.R Medical University, Chennai 
 
In fulfilment of the requirements for the award of the degree of 
 
Doctor of Medicine in General Medicine 
 
 
 
 
Under the guidance of 
 
PROFESSOR. SUJAYA MENON, M.D., 
 
DEPARTMENT OF GENERAL MEDICINE 
 
P.S.G INSTITUTE OF MEDICAL SCIENCES & RESEARCH, COIMBATORE 
 
THE TAMIL NADU DR. M.G.R MEDICAL UNIVERSITY, 
 
CHENNAI, TAMIL NADU 
 
APRIL 2016 
 
CERTIFICATE BY THE GUIDE 
 
This is to certify that the dissertation entitled, “C-REACTIVE PROTEIN AND 
GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS” is 
the bonafide original work of Dr. NANUBALA SIVA KRISHNA  in fulfilment of the 
requirements for  the degree of Doctor of Medicine in General Medicine. 
 
 
 
 
 
Signature of the guide 
 
 
Dr. SUJAYA MENON, M.D.,                                                                                                             
Professor of Medicine 
Department of General Medicine 
PSG IMS&R, Coimbatore-04. 
 
 
 
 
 
 
 
 
 
 
 
  
ENDORSEMENT BY THE HOD, DEAN / HEAD OF THE INSTITUTION 
 
This is to certify that the dissertation entitled, “C-REACTIVE PROTEIN AND 
GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS” is 
the bonafide original research work of Dr. NANUBALA SIVA KRISHNA  under the 
guidance of  Dr. SUJAYA MENON, M.D., Professor of Medicine, PSG IMS&R, 
Coimbatore in partial fulfilment of the requirements for the degree of Doctor of Medicine 
in General Medicine. 
 
 
 
 
 
 
 
 
Seal and Signature of the HOD        Seal and Signature of the Dean 
 
 
 
Dr. Jayachandran .K, MD                          Dr. Ramalingam .S, MD 
Professor & HOD,     THE DEAN, 
Department of Medicine                              P.S.G IMS&R, 
P.S.G IMS&R, Coimbatore                               Coimbatore 
 
 
 
 
 
  
DECLARATION BY THE CANDIDATE 
 
I hereby declare that this dissertation entitled “C-REACTIVE PROTEIN AND 
GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS” is 
a bonafide and genuine research work carried out by me under the guidance of                  
Dr. SUJAYA MENON, M.D., Professor of Medicine, PSG IMS&R, Coimbatore. 
 
This dissertation is submitted to The Tamil Nadu Dr. M.G.R Medical University 
in fulfilment of the University regulations for the award of MD degree in General 
Medicine. This dissertation has not been submitted for award of any other degree or 
diploma. 
 
 
 
                                                                   Signature of the Candidate 
Dr. NANUBALA SIVA KRISHNA   
 
 
 
 
 
 
 
 
  
COPYRIGHT DECLARATION BY THE CANDIDATE 
 
 
 
I, Dr. NANUBALA SIVA KRISHNA, hereby declare that The Tamil Nadu Dr. M.G.R 
Medical University, Chennai shall have the rights to preserve, use and disseminate this 
dissertation in print or electronic format for academic / research purpose. 
 
 
 
 
 
Signature of the Candidate 
Dr. NANUBALA SIVA KRISHNA   
  

 

 ACKNOWLEDGEMENT 
It gives me immense pleasure to express my heartfelt and profound sense of gratitude to my         
respected teacher and guide, Professor Dr. SUJAYA MENON, M.D., for his valuable 
suggestions, meticulous guidance, support and encouragement in doing this study. 
I am grateful to Professor and Head of the Department of Medicine Dr.Jayachandran,           
Professor. Dr. L.S. Somasundaram, Professor. Dr.Sujith Kumar, Professor. Dr. Saravanan, 
Professor. Dr. Murali, and Professor Dr. Tolstoy for their invaluable help in preparing this 
dissertation.  
I would like to thank my associate Professors,  Dr.Denesh Narasimhan, Dr.Anithkumar and       
Dr. Jagadeeswaran for their support. I am also grateful to Assistant Professors Dr.Sathish, 
Dr.Santni, Dr.Vellammal, Dr.Mohammed Zia Ansari , Dr.Anuja for their guidance. 
I am thankful to Miss.Vijayalaksmi and Miss.Kavitha, Secretaries, Department of General 
Medicine for their support. 
I would also like to extend my gratitude to the entire Department of Medicine for all the support 
throughout my course in General Medicine. 
I would also like to extend my gratitude to my friends and colleagues for their support 
throughout my study. 
I am grateful to my family members for their moral support and encouragement throughout my 
studies. 
  
 CONTENTS 
 1. INTRODUCTION        1 
 2. AIM AND OBJECTIVES      3 
 3. METHODOLOGY        4 
 4. REVIEW OF LITERATURE       5 
 5. RESULTS          65 
 6. CONCLUSION         76 
 7. BIBLIOGRAPHY         77 
 8. ANNEXURES          
 i. Proforma  
 ii. Master Chart  
  
 
 
 
 
  
  
TITLE 
 
C-REACTIVE PROTEIN AND GLYCEMIC CONTROL 
IN ADULTS WITH TYPE 2 DIABETES MELLITUS 
 
 
 
 
 
  
                                                                                          
1 | P a g e  
 
INTRODUCTION 
In worldwide, type 2 diabetes prevalence is increasing  in the  all age  group 
population. This is a major cause for death and various non fatal complications. 
In a recent study it is proved that high risk patients with type 2 diabetes mellitus 
can be reduced  by modification of life styles.[1]   
In india more then 50% of diabetic individuals, are not aware of their diabetic 
condition . As Asians are having  more waist circumference and the waist to hip 
ratio, they have more chance of having central obesity. Thus these patients are 
having greater resistance of insulin. 
In type 2 diabetes mellitus individuals, the development coronary disease is more 
common. More over, these cardiovascular events are more common in diabetic 
individuals than those without diabetics. [44] 
C-reactive protein  is synthesized in  liver. Once  tissue damage or inflammation 
occurs, CRP activates complement classical pathway, as C-reactive protein  is a 
acute phase reactant. C-reactive protein  is largely regulated by circulating levels 
of interleukin-6 predicts coronary heart disease incidence in healthy subjects.[4] 
After myocardial infarction and stroke, CRP levels rises significantly in the 
serum.[2] These  increase is observed  within 6hours of inflammation and the 
level may be up to 2000 times normal. 
                                                                                          
2 | P a g e  
 
High sensitive CRP is a measurement of CRP of lower concentration. It is a 
quantitative assay of CRP in plasma and it gives a  new method for identification 
of rupture of plaque in high risk individuals.[5] 
For the diagnosis of future myocardial infarction and stroke in a healthy men and 
women ,HSCRP plays an important independent predictor. It also has a role in 
primary prevention of cardiovascular disease.[6,7] 
For the development of cardiovascular disease, CRP and glycosylated 
hemoglobin  are having an important  increased risk factors. HSCRP indicates 
inflammation  and Hba1c indicates hyperglycemia. Both together establishes 
cardiac  risks in individual  with atherosclerosis.   
In diabetic patients, there will be development of macrovascular changes, when 
there is a poor control of glycemic level. CRP is a significant risk factor for  the 
development of  cardiovascular diasease. Increase levels of c-reactive protein ia 
also linked in increase risk for development of diabetes in later stages. 
Hence the study has been taken up to know the relation between the Hba1c and 
CRP in type 2 diabetes mellitus.   
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AIMS AND OBJECTIVES 
 
 Correlation of glycaemic control as estimated by Hba1c with C-Reactive 
protein in type-2 diabetic patients. 
 To determine if better control of Hba1c reduces CRP levels. 
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METHODOLOGY 
Prospective observational study. 
Duration of study: 12months. 
Study locale: PSG Institute of Medical Sciences and Research. 
Sample size: 30 subjects 
Inclusion criteria: 
 Patients with fasting venous blood glucose value equal or more than 
126mg/dl and post prandial glucose more than 200mg/dl. 
Exclusion criteria:  
 Patients with established coronary artery disease. 
 Patients on statins, and anti inflammatory drugs which are known to 
reduce CRP levels are excluded from the study. 
 Patients with hemolytic anemias 
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REVIEW OF LITERATURE 
CLASSIFICATION OF DIABETES: 
 Type 1 diabetes: absolute deficiency of insulin secretion 
 Type 2diabetes: combination of insulin resistance and relative insulin 
deficiency 
 Diabetes can also results from- genetic beta cell dysfunction, and exocrine 
pancreatic  diseases  or  intake of certain drugs 
DIAGNOSIS OF DIABETES MELLITUS: 
HBA1c > 6.5 %. 
OR 
Fasting >126 mg/dl. Fasting means individual should not take any food at least 
for eight hours                                        
OR 
2-hrs blood  glucose >200mg/dl .The test is performed, using a  glucose load 
containing 75 g  of glucose mixed in water 
OR 
Features  of hyperglycemia  and a blood   glucose >200mg/dl. Symptoms  of 
hyper glycemia include polyuria, polydipsea ,weight loss  
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RECOMMENDATIONS FOR ADULT WITH DIABETES: 
GLYCEMIC CONTROL TARGETS: 
Hba1c                    <6.5% 
Fasting glucose          70 -120 mg/dl 
Post prandial              >160 mg/dl 
Blood pressure           <130/80 mmhg 
LIPIDS: 
LDL                 <100 mg/dl (less than 70 in patients with established    
cardiovascular disease) 
Triglycerides             <150 mg/dl 
HDL                          in men > 40 mg/dl, in women >50 mg/dl  
FOLLOW-UP OF PATIENTS AND FREQUENCY OF TESTING 
                          TESTS           TIME  TO VISIT 
 Blood glucose                        -controlled (Hba1c<7%)-every 3 months 
-uncontrolled every 2 weeks until target 
sugars   Reached  
Hba1c       -controlled (Hba1c<7%)-6months to 1 year 
-uncontrolled every 3 months 
Tests for neuropathy 
      Monofilament                          
 
-Annual 
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      Biothesiometer 
      Foot examination 
-Annual  
-once in 3 months 
Test for retinopathy 
       Fundus examination 
 
Annually 
Tests for nephropathy 
        Urinary  micro albumin 
         s.creatinine  
 
Annual 
Annual  
Miscellaneous test:      Ecg  
       Lipid profile 
Annual 
Annual 
HSCRP 
History: 
CRP is a substance in the patients serum with active inflammation, it reacts with 
pneumococcal  c-polysaccharides. 
In 1930 HSCRP was invented by Tillett and Francis. initially CRP was thought 
that it is a pathogenic secrection, as it is increased in  various diseases, later it is 
found that it is native protein.  
Structure: 
The CRP gene is situated on the 1q21-q23 chromosome. It belongs to  pentraxins 
family. CRP contains  224 aminoacids [3] has  annular penta meric  shape. 
Function: 
CRP attaches to phosphocholine which expressed on dead and dying cell surface 
and also on few bacteria. It activates the complement pathway which promotes 
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phagocytosis with help of macrophages[4] it removes necrotic and apoptotic 
cells. 
CRP is a acute phase reactant occurs as a result of increase in IL 6 concentration 
,which is secreted by macrophages, in response to bacterial, viral and fungal 
infection with other inflammatory disease and tissue injury.  
CRP has a role in innate- immunity, as an early defense mechanism  against 
infections. 
CRP rises significantly within early hours of onset of inflammation and it reaches 
its peak at 48hours. It has a half life of 18hours. It levels are estimated by 
production rate. Thus CRP is a inflammatory marker for screening diseases. 
Clinical importance and uses: 
CRP is basically implicated as a inflammatory marker. 
Measuring CRP is helpful in assessing disease progress and efficacy of 
treatment. CRP is measured by ELISA, rapid immune diffusion and visual 
agglutination  
High- sensitive CRP measures low levels of CRP with help of laser 
nephlelometry. In 25 minutes it gives result with a good sensitivity. 
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The American heart associations have defined risk of developing cardiovascular 
disease as below [5] 
 Low :less than 1.0 mg/dl 
 Intermediate  :between 1.0 and 3 mg/dl 
 High: more than 3.0 mg/dl  
 Hs-CRP should not be indicated  alone and it should  be used along with 
increased  cholesterol levels, triglycerides  and glycemic  levels. 
HsCRP is a significant association for assessment of risk in primary prevention 
of cardiac diseases. 
In atherosclerosis, inflammation plays an important role and measuring HsCRP 
gives new method in detecting a person at risk for rupture of plaque. 
In a study that demonstrate to diagnose future myocardial infarction and stroke in 
normal healthy men and women  HsCRP plays a  good  independent marker for 
prediction.[6,7]  
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HBA1C 
INTRODUCTION: 
 In 1958 using a chromatographic column, by Hluisman and Meyering, Hba1c 
was separated from other forms of hemoglobin. In 1968 it was first identified   as 
a glycoprotein by Bookchin and Gallop. In 1969 by Samuel Rahbar, found that 
Hba1c is increased in DM. In 1975 by Bunn and his colleagues found that the 
reaction lead on  to its formation. 
In 1976 by Anthony Ceremi, Ronald Koenig and colleagues proposed that  the 
use of  HbA1c in  monitoring the  control of  metabolism of glucose in DM 
individuals. 
Principle: 
Hemoglobin a non-enzymatic reaction which  happens between sugars  and          
N-end of the betachain. It forms a Schiff base, which converts to 1-deoxy 
fructose. When plasma  glucose levels are more, these  glucose substances  
attaches  to HB in RBC. The higher the  glucose content in blood, the more 
glucose attaches  to the  HB  in the RBC and thus HBa1c is increases. Over the 
past 4weeks to 3 months, The Hba1c value  is proportional to  plasma 
concentration  of glucose [8] 
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Measurement of HBA1c: 
There are various methods for measuring HBA1c 
These are 
 High- performance liquid chromatography(HPLC)  
 Enzymatic testing  
 Electrophoresis  Capillary testing  
 Bronate affinity chromatography testing  
Introduction  and use: 
Hba1c test is done for both measuring  the plasma  glucose  control in  pre-
diabetics and monitoring  plasma glucose  control in patients with high levels.[9] 
In a  patients with diabetes, Hba1c test is done  at least twice in  a year which is 
recommended by American diabetic association. 
When Hba1c is  measured by ion-exchange chromatography ,  both in diabetic 
patients  and renal failure patients Hba1c are increased. 
As when Hba1c is measured by The  Thio barbituric acid method,even a patient 
with renal dysfunction  will have Hba1c  which is similar to normal individuals 
 The levels of Hba1c is undetermined  In autoimmune hemolytic anemia,. But by 
adding prednisolone Hba1c could  be detected[10] .The  fructosamine test is  also 
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helpful  in these situations. During pregnancy to diagnose diabetes,Hba1c is not 
necessary but require fasting blood sugars and glucose tolerance test.  
PATHOGENESIS — Type 2 diabetes mellitus  is characterized by high blood 
glucose levels and  resistance of insulin.  
In a study it showed that before making diagnosis of type 2 diabetes mellitus  in 
adults, 80% of beta cell function of pancreas is lost [11,12].  
 
FIGURE 1: PATHOPHYSIOLOGY OF TYPE 2 DM 
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Unlike type 2 DM, type 1 DM is  characterized by   absolute deficiency of 
insulin,  this deficiency   is  mediated  by T-cell  immune destruction of  beta 
cells of pancreas, and it is marked by autoantibodies of pancreas. 
 
FIGURE 2 
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FIGURE 3 
CLINICAL PRESENTATION — Childhood type 2 diabetes mellitus (T2DM) 
can present in many ways [14]: 
 Asymptomatic – Approximately 40 percent [13] 
 Symptomatic (eg, polydipsia and polyuria) without ketonuria  – 57 to 70 
percent [26] 
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 Diabetic ketoacidosis (DKA) -hyperglycemia, ketonuria, and acidosis – 5 
to 13 percent [13,15,16)] 
 Hyperglycemic hyperosmolar state (HHS) – Uncommon but serious [17-
21]DKA is more common with type-1 diabetes than individual with type-
2 diabetecs.Hyperosmolar hyperglycemic state — Adolescents with 
T2DM may present with HHS, it is  presented   high plasma glucose 
levels and  serum osmolality and severe dehydration and  little or no urine 
ketones [17].  
 HHS diagnosing is very  important as  it is characterized by very  severe 
dehydration than typical DKA, thus  has more  morbidity as well as  mortality if 
does not treat properly. 
 Indications — The American Diabetes Association (ADA) recommends 
testing asymptomatic children for T2DM if they meet the following 
screening criteria:   
 Overweight or obese  body mass index [BMI] ≥85th percentile   have 
2 or more of  risk factors described below  [22]. 
 T2DM mellitus in a first- or second-degree relative 
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 High risk racial or ethnic group: local  American, African American, 
Latino. 
 Having  insulin resistance signs, diseases  associated with  resistance 
of insulin-includes-  hypertension, dyslipidemia,  polycystic ovary 
syndrome (PCOS), or low birth weight babies. 
 History of gestational diabetes mellitus,maternal history 
Screening tests-Fasting  plasma glucose  
Oral glucose tolerance test —  OGTT is done , especially  when   diabetes 
suspicion is  high despite a FPG or A1C that is non-diagnostic.  
The FPG is less sensitive, when compare with that of  OGTT. Because FPG does 
not  detects  diabetes early in establishment  of their disease [23] 
The standard glucose load used for the OGTT is with adose of 75 g can be given  
and results are interpreted as follows: 
 Blood  glucose ≥200 mg/dL observed  2  hours after the sugar load is 
diagnostic in  diabetes individual 
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 Blood  glucose ≥ 140  to 199 mg/dL  observed  2  hours after sugar  
load demonstrates impaired glucose tolerance (IGT), and indicates 
increased risk for diabetes,  
PREDIABETES: It is diagnosed if any of following are there   
 Impaired fasting glucose (IFG) – Fasting plasma sugars   ≥100  to 
125 mg/dL. 
 IGT  – blood  glucose ≥140  to 199 mg/dL  measured two hours after a 
glucose load  
 Hemoglobin A1C level is  between 5.7 and 6.4 % (39 to 
46 mmol/mol) have also been considered to indicate risk for diabetes 
and have been viewed as prediabetes in adults;  
Diabetes related microvascular and macrovascular complication: 
In type 2 diabetes mellitus the vascular disease  are  caused by hyperglycemia, 
insulin resistence, dyslipidemia and  hypertension and  obesity as well. 
The Mechanism of these vascular diseases include glycation of end product 
accumulation , dysfunction of smooth muscle cell , over production of 
endothelial derived  growth-factors,  long term inflammation, fibrinolytic 
dysfunction , enhancement of aggregation of platelets. 
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 Both microvascular and macrovascular complications are more common with  
DM which includes retinopathy, nephropathy, neuropathy and IHD ,peripheral 
vascular diseases and cerebrovascular diseases respectively, which in turn  result  
in damage of both tissues and organs. 
Microvascular changes  of  DM : 
Diabetic- retinopathy:(DR) 
Diabetic- retinopathy is the leading cause of  blindness in the middle aged  
people .The exact mechanism by which diabetes causes retinopathy remains to be  
unclear[44,45] 
Signs and symptoms: 
Initially these patients are generally asymptomatic, and in the advance stage of 
the disease they may expirence blurred vision , distorsion and progressive loss of 
visual acquity. 
Signs  include 
 Microaneurysms: these are earliest sign of diabetic retinopathy. occurs 
secondary to capillary wall outpouching because of pericyte loss. seen 
in superficial retinal layer 
                                                                                          
19 | P a g e  
 
 
FIGURE 4 
Long arrow indicate blot hemorrhages, short arrow-microaneurysms, arrow head-
hard exudates 
 Dot and blot hemorrhages 
 Flame-shaped hemorrhage 
 Retinal edema and hard exudates 
 Macular edema 
Diagnosis: 
 Fluorescein angiography 
 B-scan ultrasonography    
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Management: 
 Glucose control 
 Laser photocoagulation 
 Vitrectomy 
 Cryotherapy 
Diabetic- neuropathy: 
 Neuropathy is one of the important  complication of DM 
 Most of the diabetic individual has neuropathy in form of diabetic  
polyneuropathy ,mono neuropathy  and also the autonomic neuropathy.  
Clinical features : 
In type 1 diabetes mellitus  symptoms of neuropathy occurs later stages of 
disease, where as in  type 2 diabetic individuals  neuropathic symptoms occurs 
early stages of diabetes.[46] 
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These symptoms  include: 
 Sensory symptoms occurs  in form of glove and stocking  involvement in 
the distal parts.  
 Motor involvement occurs in  the proximal and also distal parts. 
 Autonomic features  which includes- cardiovascular,genitourinary 
systems and gastrointestinal 
Diagnosistic tests: these are 
 Fasting  plasma  glucose 
 HBA1C 
 CBC, fasting  B-12 and folate levels,  and TFT  
Other diagnostic tests include: 
 Nerve conduction studies 
   Electro physiologic tests 
Management: 
 Foot care  includes –regular follow up and patient education 
 Tight glycemic control 
 Pain management by pregabalin, gabapentin, sodium valprovate 
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 Treatment of diabetic gastroparesis which include metoclopramide, 
cisapride, erythromycin and polyethylene glycol[47] 
Surgical treatment include: 
 Aggressive debridement for foot necrosisor infection 
 Jejunostomy in case of recurrent  gastroparesis 
Diabetic nephropathy: 
In both type 1 and type 2 Diabetes mellitus, it is  serious  complication .The 
earliest finding  would be  micro albumi nuria (300mg/d) which develops  to 
overt  albumi nuria which finally  leads to renal dysfunction  and this  lead on to 
cause  end stage kindey disease. 
Another  important  features of  DN are  glomerular basement membrane  
thickening  & hyperfiltration lead on  to expansion of  mesangial extracellular 
matrix  and which  ultimately progression  to renal failure. 
The  factors causing   DN are hyperglycemia, diabetes duration, , dyslipidemia, 
SHT and also obesity.   
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Management include 
 Good glycemic control  
 Control of hypertension by ACE and  ARB inhibitors  
 Renal replacement therapy  with end - stage renal disease 
Macro-vascular changes  of diabetes: 
Main mechanism in the macrovascular changes is the formation of 
atherosclerosis, and this  lead on to stenosis of arterial wall in whole body.   
 The genesis of atherosclerosis is due to  injury to  coronary  as well as peripheral 
vessels  and also  due to chronic inflammation.  
Apart from occurrence  of atheroma, there will be a significant  platelets 
adhesion and also  hyper-coagulability in these  type- 2 diabetic individual. 
Diabetes increases the risk of developing cardiovascular disease but exact 
mechanism by which it occurs is not known, patients with type- 1 or type -2 DM 
cerebrovascular disease   is the major  factor  for  death. [48,49] 
Of all  macrovascular complication of diabetes, Coronary artery  disease  has 
significant association  with DM,Framingham study.[50].    
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Type 2 diabetes itself is a risk factor in developing  cerebrovascular disease, 
myocardial infarction and death  [51] . In individuals  with type 2 DM, women 
are at risk in developing coronary artery disease than men population. [52]  
In a patient with type-2 DM, treating hypertensive individuals  and achieving 
good glycemic levels can reduce the macrovascular events and also mortality 
efficiently.   
In a study showed that,treating the hypertensive individuals can significantly 
reduces  the macro vascular events in patient with diabetes. [53,54] 
ACE and ARBs acts by inhibiting the rennin angiotensin system , and there by 
reduces the cardiovascular events significantly when compared with other 
antihypertensive agents.[55,56] 
 In diabetic patients,the use of statins  can also reduces the macrovascular  
complications significantly.  
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FIGURE 5 
NO- Nitric oxide,  tPA - Tissue plasminogen activator-1, PAI-1-plasminogen activate or 
inhibitor 
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Cardiovascular disease in patients with diabetes: 
 In finish cohort study ,among subjects with type 2 DM without prior CHD 
the risk of MI was high as those without diabetes with previous MI  i.e 
diabetic patient without prior CHD have the same event rate compared to 
nondiabetics with prior vascular disease 
 Coronary artery disease is 3 to 4 times more common in patients with 
diabetes  
 Sudden death is 50% greater in males and 100% greater risk in female 
compared to non diabetic patients 
 There is loss of premenopausal protection in females  
 Unexplained cardiac failure, fatal arrhythmias, hyperglycemia complicate 
the acute coronary syndrome 
 Atypical presentation delays prompt treatment. diabetic autonomic 
neuropathy may mask symptoms and episodes of silent ischemia may 
occur 
 Associated diabetic cardiomyopathy may worsens the outcome 
 Revascularization procedure have less favorable outcome and restenosis is 
more common 
 CHD is the commonest cause of mortality in diabetes with renal failure 
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PATHOGENESIS OF CHD: 
CHD risk factors like hypertension, dyslipidemia , obesity, Insulin  resistence, 
aggregate in patients with diabetes .These  atherosclerosis occurs due to 
atherogenic factors in diabetes : 
Hyperglycemia and other metabolic abnormalities: The excess risk found in 
diabetes which cannot be attributed to interaction between other risk factors is 
supposed to be mediated by hyperglycemia per se.  
Insulin resistance and hyperinsulinemia: It is an underlying link between 
hyperglycemia and CHD.These patients have increased proinflammayory 
markers. 
Obesity: intra-abdominal obesity is associated with insulin resistance .this is 
associated with an increased influx of free fatty acids to liver. 
Atherogenic dyslipidemia of diabetes: It is best characterized risk factor.the 
decreased HDL levels and infective HDL in diabetes also worsens 
atherosclerosis.[44] 
Hypertension: More than half of the patients with diabetes have hypertension 
even at the time of diagnosis. 
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Endothelial dysfunction: Decreased nitric oxide availability  and impaired 
endothelial vasorelaxation  increased response to endothelian-1 and altered 
permeability are found more in diabetic patients. 
Low grade inflammation and fibrosis: increased CRP and cytokines  like TNF-
alpha activate and sustain atheroma formation. 
CLINICAL MANIFESTATIONS: 
 Angia or acute coronary syndrome  
 Silent ischemia in the presence or even absence of cardiac autonomic 
neuropathy 
 Atypical ischemic symptoms like dyspnea, hypotension, sweating, 
syncope and vomiting and fatigue 
  Cardiac failure 
 Complications following MI like shock, conduction disturbances, cardiac 
failure and ketoacidosis 
 Fatal or non fatal dysrhythmias 
A high index of suspicion is always necessary in patients with diabetes 
SCREENING FOR CORONARY ARTERY DISEASE IN DIABETES:  
The goal of screening in these individuals  with Coronary artery disease is 
to identify people  with more  cardiac risk, and their outcome could be improved 
with  life style  modification or with recanalisation  of the CAD. 
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Indications for testing of CAD:  
1) Those with atypical  symptoms 
2) Baseline  ECG indicative  of either  ischemia or infarction 
Cardiac testing: 
 Resting ECG-low sensitivity 
 Holter monitoring –has usefulness to detect arrhythmias ,as it is usually 
done for 24 or 48 hours period  
 Stress ECG-exclude triple vessel disease but not single or double disease  
 Stress echocardiography: It is  done using dobutamine .induced regional 
wall motion abnormalities during stress echo is sensitive marker for 
ischemia. It is cost effective and reliable but more operator-dependent. 
 Angiography: It is currently gold standard in evaluation of coronary artery 
disease .The introduction  of newer methods includes- intravascular 
ultrasound  (IVUS) and flow wire to check  coronary fractional flow 
reserve (FFR) in patients with CAD. 
 Magnetic resonance imaging for heart (MRI):It is another rapidly 
emerging technology  for imaging the heart including the coronaries. 
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 Positron emission tomography(PET-CT)-PET allows quantification of 
absolute myocardial perfusion and also gives information of myocardial 
metabolism using radioactive metabolic markers.   
MANAGEMENT: 
Differences in management strategies and outcome are due to: 
 Atypical symptoms 
 Requirement of repeated interventions and longer hospital stay 
 Higher incidence of postintervention and complications 
Lifestyle modification: Regular exercises –walking, jogging cycling or 
swimming  
 Limitation of fat and total energy intake  
 Cessation of smoking 
Glycemic control: Even the base line HbA1c  at the time of diagnosis of 
diabetes has been shown (UKPDS 66) to predict the future cardiovascular 
outcome. 
 For every increase in HbA1c by 1 percent there is an 11% increase in 
CAD (UKPDS study). 
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 Hence in these patient with diabetes  a HbA1c  of <7% should be the 
target to prevent macrovascular disease. 
 Metformin -  shown to decrease  coronary symptoms in  subjects if not 
contraindicated.  
Control of blood pressure: target to keep the BP< 130/80 mmhg.drug 
therapy includes ACEI or ARB. 
Lipoid management: Also plays an important role  
Antiplatelets therapy: Aspirin therapy as a primary prevention strategy 
should be considered in those with type 1 or 2 diabetes  with increase 
cardiovascular risk-men >40 years  of age and female >60 years. 
Muitiple risk factor modification:The STENO-2study showed that 
intensive therapy targeting multiple risk factors in addition to hyperglycemia 
can reduce cardiovascular mortality. 
Cerebrovascular diseases: 
It include: 
1)  cerebral artery diseases  
2) Cardiac diseases  which may adversely affect blood supply to the brain by 
changes in the blood pressure or as a source of emboli. 
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3) Blood  disorders  which  leads  to clotting  impairment , which ultimately 
causes thrombosis in the cerebral vessels. 
Stroke: is defined as sudden loss of function of brain due to alteration in  blood 
supply to brain. stroke is not a diagnosis but a clinical syndrome with has variety 
of causes which may include: 
 Cerebral infarction 
 Intracerebral hemorrhage 
 Subarachnoid hemorrhage 
 Cerebral venous thrombosis 
Main risk factors for stroke:[45] 
 Major risk factors: 
1) Hypertension  
2) Cardiac disease-IHD,atrial fibrillation 
3) Transient ischemic attacks 
4) Cigarette smoking  
5) Alcohol 
6) Hyperlipidemia –elevated LDL cholesterol 
7) Oral contraceptives 
8) Obesity 
9) Diabetes mellitus 
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Associated risk factors: 
1) Diabetes mellitus 
2) Previous stroke 
3) Raised hematocrit 
4) High plasma fibrinogen 
5) Antiplasmalipid antibodies (APLA) 
6) Asmptomatic carotid arterial lesions 
Ischemic stroke: 
Transient ischemic attack (TIAs)-an episode of acute neurological deficit. 
MRI must not show evidence of acute ischemia irrespective of the time period of 
recovery, occurring as a result of reduced flow to a vessel from fall in perfusion 
pressure. Or blockage of passage of flow by embolism arising from plaque in 
aortic arch, from heart.   
Cardiac embolism from thrombus in left atrium or ventricle  
Less common causes of stroke: 
1) Hematological abnormalities: That promote thrombosis  
                  Eg: polycythemia and thrombocytopenia. 
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        Anticardiolipin antibodies may cause acquired abnormalities of 
thrombolysis  and are associated with stroke in younger patients. Thrombophilia 
may cause cerebral venous thrombosis. 
2) subclavian steal  :it is an uncommon cause of hemodynamic symptoms.if 
subclavian artery is occluded or stenosed before the origin of vertebral 
artery,arm exercise may cause retrograde flow down the vertebral artery at 
the expense of the vertebrobasilar  circulation,resulting  in brain stem TIA. 
3) Magraine:is a rare cause of cerebral infarction. Headache is common in 
ischemic stroke and may be caused by collateral vasodilatation or carotid 
dissection. 
4) Vasculitis :it is a rare cause of both hemorrhagic and ischemic stroke 
.these usually include SLE, polyarteritis nodosa(PAN), giant cell arteritis. 
5) Silent cerebral infarction-many middle aged and elderly patients with 
hypertension without  a history of  stroke or TIA have small infarcts 
lacunes or patchy ischemic periventricular imaging abnormalities 
(leukoaraiosis) on CT or MRI. 
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Investigation  and diagnosis of a cerebrovascular accident: 
I. History:  
1) Age- in a young patient consider : 
 Cardiac disease-infective endocarditis,atrial fibrillation,mitral 
valve stenosis 
 Vascular disease-severe hypertension, hypercoagulable 
state,vasculitis 
 A-V malformation/aneurysm 
 Intracranial space occupying lesion 
 Encephalitis eg:HSV type 1  
 Post-ictal 
 Migraine  
 Hysteria 
 Hyperventilation 
2) History of previous minor episodes:may suggest disease of 
carotico-vertebral system of embolic disease from arteries or 
from heart.history of migraine or epilepsy should take into 
consideration.. 
3) History of head injury:depressed fracture and subdural 
haematoma 
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4) History of drugs: eg-contraceptive pills,anticoagulants. 
5) Family history-history of stroke and early age of onset may 
suggest familial trait to atherosclerosis 
6)  Past history: of diabetes, hypertension or cardiac disease  
II. Physicial examination: 
A. Neurologic : 
1. State of consciousness-may vary from full alertness to 
lethargy,stupor,semiconscious or coma 
2. Speech: should be evaluated to differentiate between slurred 
dysarthric speech and dysphasic speech. 
3. Neck rigidity-subarachnoid hemorrhage and meningitis   
4. Focal neurologic deficit-Tests for hemiparesis,hemianopia  
B. General – 
1. Blood pressure-for arterial hypertension  B.P should be checked in 
both arms because of possibility of aortic arch syndrome. 
2. Heart-for cardiac arrhythmia such as atrial fibrillation  or recent MI 
3. Bruits: due to stenosis .over carotid and subclavian arteries ,bruit 
produced by stenosis in vertebral arteries. 
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III. Investigations: 
CT scan- To establish the pathological diagnosis (infarction or 
hemorrhage) and to exclude other conditions that mimic stroke ( 
eg.subdural hematoma, intracranial tumour) 
All patient must undergo scanning within 24 hours.  
Magnetic resonance techniques: MRI is more sensitive to small areas 
of ischemia than CT and can detect traces of old hemorrhage 
Carotid uitrasonography: To identify carotid artery stenosis,occlusion 
and dissection. 
Management:[46] 
Acute ischemic stroke: 
General treatment - it has  cardiac care , decrease the   BP, prophylactic 
measures against DVT, aspiration pneumonia. 
Specific treatment: 
a) Thrombolysis is being  with recombinant –tissue plasma activator 
(rT-PA)  dose is 0.9mg/kg  is  given  within 4 hours of  ischemic 
stroke  with 10% as bolus  and remainder of the drug by infusion 
over 1 hour. 
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Indications of thrombolysis: 
Absolute indications includes 
 When patient reaches hospital within 3 hours of symptoms onset 
    CT scan should not show any hemorrhage 
Contraindications includes 
   In last 3 months, there should not be any head trauma 
 Systolic BP above 185 or diastolic  >110 mg/dl 
 When patient is recovering from weakness 
 Symptoms of  SAH 
 Platelets count < 1,00,000 
 Peripheral vascular disease 
The prevalence of peripheral artery disease (PAD) rises  significantly  with age, 
occurring  after 40 years.[47] Thus  PAD is causing a problem in the older 
individuals. 
 So whenever examining the elder individuals, it should be kept in mind  to 
ask questions related to history of PAD which includes -history of 
walking impairment after walking for some distance and, and the presence 
of nonhealing wounds.  
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 Risk factors for these  peripheral artery disease includes - smoking, 
hypertension, hyperlipidemia, diabetes, and metabolic syndrome.  
Other factors include age, gender, ethnicity, family history and genetic 
influences, and possibly homocysteinemia.  
 The following  groups are  at risk for developing  PAD: 
Age ≥70 years 
Age 50 to 69 years with a history of smoking or diabetes 
Age 40 to 49 with diabetes and at least one other risk factor for atherosclerosis 
Leg symptoms suggestive of claudication with exertion or ischemic pain at 
rest[48] 
Abnormal lower extremity pulse examination 
Known atherosclerosis at other sites (eg, coronary, carotid, renal artery disease) 
Prevalence of PAD rises with the age and occurs  after  40 years. Individuals 
over 70 are at a significantly increased risk for PAD due to age alone, while the 
risk for younger individuals is due to other factors, most commonly cigarette 
smoking. Early-onset atherosclerosis, or premature atherosclerosis, is defined as 
PAD presenting prior to 50 years of age. Patients with early-onset atherosclerosis 
more often present with critical limb ischemia and have poor overall outcomes.  
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 Gender and ethnic-related differences in prevalence of PAD have been 
documented.  
Peripheral vascular disease occurs more commonly in men when compared 
with female population. Another scenario is peripheral vascular disease is 
more common in females over 70 years of age when compared withmen of 
same age group. 
 The natural history of peripheral artery disease in patients who present 
initially as asymptomatic or with mild to moderate intermittent 
claudication is relatively benign. Of those with intermittent claudication, 
70 to 80 percent people  have stable claudication, 10 to 20 %  develop 
worsened claudication and only about  2 percent of population   develops  
critical limb ischemia. [48] 
The outcome for limb loss and  survival is  worsens  in individual  with 
early-onset atherosclerosis, patients with diabetes or end-stage renal disease, 
and for those who continue to smoke. 
Management: 
The management of patients with claudication due to atherosclerotic disease is 
aimed at lowering the risk of cardiovascular disease progression and 
complications, and improving claudication symptoms. 
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Medical management involves risk factor modification, exercise, and possibly 
pharmacologic therapy to improve walking distance 
Claudication has  more  risk of MI , cerebrovascular, and renovascular illness. 
Thus  peripheral artery disease  is assumed  to be equivalent  to  coronary cardiac  
disease. 
To reduce the cardiovascular disease progression and complications, a secondary 
prevention strategy these  includes antiplatelet therapy ,smoking cessation, 
control of blood sugar and blood pressure, lipid-lowering therapy, and dietary 
modifications  to achieve the goals set in national guidelines.  
Usually the  use of  dual antiplatelet therapy is not recommended  in patients 
with claudication in the absence of other indications (eg, drug-eluting stent, 
prosthetic distal lower extremity bypass 
For most patients with lifestyle-limiting claudication who do not have an 
improvement in symptoms with risk modification and exercise therapy, a 
therapeutic trial of naftidrofuryl or cilostazol (100 mg twice daily).  
Naftidrofuryl has fewer side effects, [49] 
We schedule follow-up after three months to assess the effectiveness of the initial 
medical therapy regimen for reducing symptoms. [50] 
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Patients who show improvement and who are satisfied with their progress can be 
scheduled for annual vascular examination.  
For patients who have been compliant with risk reduction strategies, yet six 
months to a year of exercise therapy and adjunctive pharmacotherapy have failed 
to provide satisfactory improvement, referral for possible revascularization is 
appropriate. 
Options for revascularization include percutaneous intervention, surgical bypass, 
or a combination of these, and the choice depends upon the level of obstruction 
(aortoiliac, femoropopliteal) and severity of disease, and the patient’s risk for the 
intervention.  
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Mechanisms for both Micro and Macro vascular complications  of Diabetes
 
FIGURE 6  
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Mechanisms of diabetes –associated with  dysfunction of endothelial cells 
AGE - Advanced glycation end products  
RAG - Receptors for AGE, 
ROS - Reactive oxygen species 
PKC - Protein kinase c 
RAS – Renin angiotensin system  
MANAGEMENT OF DIABETES MELLITUS: 
Treatment of non insulin dependent DM: 
 Principles: 
 Accurate  diagnosis is important. So that  diagnostic criteria  can be  
applied. 
 Management  must not be considered decreasing  the plasma  glucose 
alone and  also must  look into any associated CVD risk factors. 
 Management of NIDDM requires teamwork. 
 Self monitoring improves quality and safety of treatment. 
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GENERAL OBJECTIVES OF DIABETIC MANAGEMENT: 
 To improve the  symptoms 
 To treat the  associated health issues  and lower the   mortality  in the  
population  
 To improve  the productivity of a  person  and  also the  life quality of a 
person  with diabetes 
TREATMENT MEASURES: 
Glucose control — good  glucose  control, significantly  reduces  the  
microvascular changes  in  type-2 DM individuals [57]. 
Every 1 %  decrease  in HBA1C the outcome of disease would be better    
Along with  lowering the blood glucose levels, we should also look into other 
factors such as   cessation of smoking, use of clopidogrel and good control of 
blood pressure and also lowering the lipid levels and physical activity. All these 
thing plays a role in reducing the cardiovascular complications in patients with 
type-2 DM. 
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DIABETIC NURSING EDUCATION: 
In patient with newly detected diabetics, the role of physical activity and life 
style modifications and good glycemic control  should be told clearly in order to 
prevent future complications of diabetes.   
In a small study ,it has been showed that, diabetic individuals who took part in 
diabetic nursing  education has significantly  reduces  the Hba1c than people who 
have not participated  in nursing education. [58]  
Weight reduction — For people  with  diabetes those  are overweight i.e BMI ≥  
25 to 29.9  and obese i.e BMI ≥30 should be told to decrease  the intake  of 
calories and to involve  in physicial activity at least 1hr in a day.   
Diet — Weight loss through diet modifications  would  benefit   diabetes 
individual , including glycemic control and also  hypertension.  
Exercise — individual  with diabetes are  motivated  to do physicial activity at 
least  30 to 60 minutes of moderate excreise, in  most of the  days in a week. 
Regular physicial  exercise has a  role in  diabetic  individual,which is a 
independent factor for  weight loss. Which   improves  glycemic control because 
of increased response  to insulin; thus it may   delays  progression of decrease  
glucose tolerance  to the established  diabetes [59,60].  
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Pharmacologic therapy — drugs  for  the weight loss could  be better  in 
individual with  diabetes, but it has got many side effects and more over it is not 
used as initial therapy in diabetics [61]. 
 
FIGURE 7 
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Factors favoring  non insulin dependent  diagnosis of  DM:  
 Classical  diabetes features are absent 
 Older age group people  i.e more than  30 years 
 Having   obesity 
Initial assessment : 
 A full history is  required  and also the   symptoms and  the focus must  be 
emphasized  on 
 cardiovascular diseases Risk factors 
 Cardiovascular complications symptoms include angina, heart failure and 
claudication 
 Ocular symptoms 
 Neuropathic complications symptoms includes numbness, pain, muscle 
weakness 
 Drug history 
 Gestational history 
A complete examination includes 
 Height and weight measurement 
 Blood pressure measurement 
 Examination of Cardiovascular system and peripheral pulses 
  Fundus examination 
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 Laboratory assessment should include: 
  blood glucose measurement 
 Urine  for ketones bodies; glucose and also proteins  
 All individual with proteinuria, s.creatinine is to be  done  
 ECG 
 Blood cholesterol level 
 HBA1c measurement 
 
Management of DM: 
The major component  are : 
1.Dietary  modifications 
2.OHA’S 
3.Insulin treatment 
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FIGURE 8 
Source-WHO/EURO  
*Drug therapy should be considered at this stage in presence of high sugar 
levels or conditions associated with infection. 
** if no contraindication,can be used 
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Dietary management: 
 Diet is essential in treatment  of  diabetes . 
Dietary management  must  look  at: 
 Emphasis on  control of weight 
 Adequate  nutritional requirement 
 Allow better  control of glycemic level 
Meal planning: 
 Diet counseling must  be told   in every visit 
 Meals must be evenly distributed through out the day 
Activity: 
 Physical exercise  ensures reduction in weight ,it  mproves  insulin 
sensitivity ,so that   lowers the plasma sugars  levels. 
Drug management: 
 Antidiabetic drugs  are used only, when the  diet and exercise are failed to 
achieve the better glycemic control. 
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FIGURE 9 
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Types of OHA: 
 
FIGURE 10 
1) Sulphonylureas (sus) act  on beta cells and relases the insulin  and it  
promotes  its action via extra pancreatic mechanism. 
Ex: glibenclamide,glipizide,gliclazide,glimepride 
2) Biguanides acts  by lowering the  gluconeogenesis and increases  
peripheral glucose  utililise by the cells. 
Ex:Metformin 
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As metformin causes lactic acidosis it is should not be used  in 
 Altered  renal function 
 Age group  >70 years 
 Patient with heart failure and hepatic impairment 
Both SU and BGs must  not be given  during pregnancy and  breast –feeding 
patients 
3) Alpha glucosidase inhibitors: its acts by inhibiting carbohydrate 
absorption in the gut 
Ex:acarbose,  
4) Thiazolidinediones: its improves peripheral insulin sensitivity  
      Ex:pioglitazone, voglibose,miglitol 
5) Dipeptidyl peptidase inhibitors(DPP): acts by glucose induced insulin 
response             
Ex:vildagliptin,sitagliptin,saxagliptin,linagliptin 
6) Dopamine agonist: acts by hypothalamic dopamine release 
      Ex:bromocriptine 
 
                                                                                          
55 | P a g e  
 
Antidiabetic drugs with their mechanism of  actions and limitations: 
 
In patients with non insulin dependent DM , insulin is used  in few  conditions 
:these are  
 When adequate diet and OHAs are failed to lower  hyperglycemia 
 In gestational diabetes mellitus, even after dietary modifications  
 Sometimes when these   OHAs are  being contra indicated 
 In case of  infections and when surgery is planned 
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Insulin management : 
Individuals with diabetes must   
 Be taught   techniques of self measuring of glucose levels  
 Keep a record of self monitoring results 
MANAGEMENT OF INSULIN DEPENDENT DIABETES 
MELLITUS:(IDDM) 
Specific objectives: 
Goal in insulin dependent DM in the children  is to make sure that they have  
adequate  growth and the  development . so the measure can be explained to the 
family members of a child.  
Assessment: 
 Thyroid function and thyroid function tests. 
 Measure the height and weight of a child  
 Monitor the growth regularly  
Insulin therapy goals: 
 Reaching the adequate  metabolic control and  mimicks the  secretion of 
insulin  physiologically 
 Minimize the risk of hypoglycemia 
                                                                                          
57 | P a g e  
 
Insulins are routinely administered  by subcutaneous(s.c) route, and  In diabetic 
ketoacidosis.(DKA)  it can administered by either IM or IV routes. 
In all individuals with insulin dependent DM, self monitoring shall be 
emphasised 
Follow-up: 
During review blood glucose monitored and measurement  of Hba1c,urine 
glucose and ketones are checked. Annual eye examination and microalbuminuria 
are recommended. 
INSULIN THERAPY: 
Sources of insulin: 
sources of insulin include: beef, pork, human  
Classification of insulin: 
 These include meal time (bolus) and basal insulin. 
 Meal time insulins are rapidly acting analogs or short acting regular 
human insulin .these have been used to stimulate high levels of insulin 
seen in individuals without diabetes after ingestion of food. 
  Intermediate and long acting human insulins  are Basal insulins  and 
analog 
                                                                                          
58 | P a g e  
 
Classification is based on duration of action 
Basal insulis: 
1) Neutral protamine hagedorn (NPH) 
2) Isophane insulin  
3) Ultralente (extended insulin zinc suspension) 
4) Insulin analogs: Detemir, glargine 
Bolus or meal time insulins: 
1) Regular insulin 
2) Analog forms:Aspart,lispro   
Premixed Insulin: 
The most commonly used premixed insulin is 30/70  
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HUMAN INSULIN ANALOGS 
Source: NEJM 
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SOURCE:NEJM 
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INDICATIONS FOR INSULIN THERAPY: 
 Type 1 diabetes 
 Type 2 diabetes who have failed to achieve glycemic goals with the 
maximal dose of OAD’s 
 Gestational diabetes 
 In  type- 2 diabetes during   physiological stress-surgery,infection,acute 
illness 
 Diabetic ketoacidosis/ hyperosmolar hyperglycemic nonketotic coma 
 Secondary diabetes (pancreatitis,steroids) 
 Chronic renal failure 
 Use of parenteral nutrition or high calorie supplements  
Site for insulin administration : 
1. Anterior abdominal wall: Rate of absorption of insulin is more rapid and 
more consistent in the abdomen than in the arms, thighs. reasons are easy 
self administration, larger surface area,. 
2. Insulin is injected at least 4 finger breadths away from the umbilicus on 
all sides 
3. Upper outer thigh: 
 Issue of privacy especially  among women 
 Exercise may increase the insulin absorption 
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 And has very little subcutaneous tissue laterally, so injections in 
thigh are not preferred. 
4. Upper outer arm: 
 Self administration of insulin in the arm is difficult. 
  
Factors that affect the rate of insulin absorption: 
Site of injection:  
After injection into the arm and abdomen  peak concentration of insulin is 
reached at 75min and 60 minutes respectively. The shorter absorption time from 
the abdominal site means that there is less destruction of insulin by subcutaneous 
tissue. 
Temperature: 
The warmer the area ,the faster is the absorption,the colder the area,the slower 
the absorption. 
Exercise: 
Exercise  increase the rate of absorption of insulin by increasing the blood supply 
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Complication of insulin therapy: 
 Hypoglycemia 
 Weight gain 
 lipohypertrophy 
Alternative methods of insulin delivery: 
 Temporary pen device 
 Permanent pen device 
Advantages of insulin pen devices over conventional insulin syringes : 
 more convenient method and more accurate insulin delivery 
 less pain because of smaller gauge needle 
 improved quality of life 
 improved social acceptability especially at schools 
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INSULIN PUMPS: 
Continuous subcutaneous insulin infusion(CSII): 
The system consists of  a pump ,a reservoir syringe,and infusion set with a 
Teflon catheter that is inserted into  subcutaneous tissue.The reservoir 
accommodates a volume of  3ml/300 u and has to be  disposed after each use.The 
infusion set needs  to be changed once in every 2 to 3 days to maximize the 
benefit of pump therapy. 
Benefits of CSII: 
 Closer to normal blood glucose levels throughout the day –with in the 
target range 
 More approximate matching of insulin to food intake  
 Improved changes for a long ,healthy life 
 Increased coping with daily living 
 Improved targeting of dawn phenomenon     
Risks of CSII: 
 Diabetic ketoacidosis 
 Hypoglycemia 
 Catheter site infection and contact  dermatitis  
 Weight gain 
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RESULTS 
 The study was conducted in 30 patients of type 2 diabetes mellitus who had been 
admitted in PSG hospitals attached to MGR HEALTH UNNIVERSITY, 
COIMBATORE,TAMIL NADU  during the period from November 2014 to may 
2015.All cases met inclusion and exclusion criteria.The observations made in this 
study are discussed here.  
TABLE 1: AGE  
Age group Frequency Percentage (%) 
40-50 yrs 6 20.0 
50- 60 yrs 10 33.3 
60 – 70 yrs 12 40.0 
>70 yrs 2 6.7 
Total 30 100.0 
 
In a study population of 30, 40% of people are between the age group of 60-70 years. 
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FIGURE 11 
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TABLE 2: GENDER 
Sex Frequency Percentage (%) 
Male 13 43.3 
Female 17 56.7 
Total 30 100.0 
 
 
 
FIGURE 12 
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TABLE 3: HBA1C-At Baseline 
HbA1c Frequency Percentage (%) 
8-9 5 16.7 
9-10 8 26.7 
10-11 6 20.0 
>11 11 36.7 
Total 30 100.0 
 
In the study population of 30 , 36.7% of people are having HbA1c of >11 % and 
16.7% of people are having HbA1c  between 8-9. 
 
FIGURE 13 
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TABLE 4: HbA1C- After 6 months 
HbA1c Frequency Percentage (%) 
8-9 21 84.0 
9-10 2 8.0 
>11 2 8.0 
Total 25 100.0 
 
In the  study population of 30,. after 6months ,84 % of people are having HbA1c 
between 8-9 and 8% of people are having 9-10 and >11 % respectively 
 
FIGURE 14 
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TABLE 5: HsCRP- At Baseline 
HsCRP Frequency Percentage (%) 
<5 19 63.3 
5-15 3 10.0 
15-25 6 20.0 
>25 2 6.7 
Total 30 100.0 
 
In the  study population of 30,at baseline 63% of people are having hsCRP of <5% 
and 6.7 % of people  are having >25.  
 
FIGURE 15 
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TABLE 6: HsCRP - After 6 months 
HsCRP Frequency Percentage (%) 
<5 12 48.0 
5-15 11 44.0 
15-25 2 8.0 
Total 25 100.0 
 
In the  study population  after 6 months, 48% of people are having hsCRP of <5 and 8% 
of people are between 15-25   
 
FIGURE 16 
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TABLE 7: Descriptive Statistics 
 Mean Std. Deviation N 
HBA1C- At baseline 10.4037 1.51596 30 
HSCRP- At baseline 7.9047 9.75382 30 
HBA1C- After 6 months 8.4296 1.84054 25 
HSCRP- After 6 months 4.8780 5.41332 25 
 
 
FIGURE 17  
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TABLE 8: Correlations 
  
HBA1C- At 
baseline 
HSCRP- At 
baseline 
HBA1C- 
After 6 
months 
HSCRP- 
After 6 
months 
HBA1C- At baseline Pearson 
Correlation 
1 .209 .105 .129 
Sig. (2-tailed)  .267 .619 .540 
N 30 30 25 25 
HSCRP- At baseline Pearson 
Correlation 
.209 1 .183 .654
**
 
Sig. (2-tailed) .267  .380 .000 
N 30 30 25 25 
HBA1C- After 6 
months 
Pearson 
Correlation 
.105 .183 1 .037 
Sig. (2-tailed) .619 .380  .860 
N 25 25 25 25 
HSCRP- After 6 
months 
Pearson 
Correlation 
.129 .654
**
 .037 1 
Sig. (2-tailed) .540 .000 .860  
N 25 25 25 25 
**. Correlation is significant at the 0.01 level (2-
tailed). 
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FIGURE 18 
8
10.43
14.2
13.8
8.2 8.35
10.94
15.2
9.68
8.31
13.8
8.1
11.43
9.39 9.35 9.45
9 8.84
8.19
11.1
10.3
9.04
8.1 8.1
9.3
8.41
9.14
14.9
11.3
8.81
6.1
13.2
11.2
9.85
7.03
6.1
7.3
6.2 6.4
6.87
7.82 09
6.3 6.2
8.8
8.02
6.28
6.89
6.23
7.8
6.02
8.4
9.1
6.4 6.2
0
2
4
6
8
10
12
14
16
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30
p value= 0.334
HBA1C- At Baseline HBA1C - After 6 months
                                                                                          
75 | P a g e  
 
 
FIGURE 19 
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CONCLUSION 
Hba1c at baseline, minimum value is 8 and maximum is 15.2. Hba1c after 6 
months, minimum value is 6 and maximum is 8.3.  
So in this study when hba1c is compared with baseline hba1c ,patient has got 
good glycemic control,but stastically not significant [p>0.05] 
HSCRP at baseline, minimum value is 10 and maximum is 32. Hba1c after 6 
months, minimum value is 2 and maximum is 20.4.  
So in this study when HSCRP is compared with baseline HSCRP, shows 
stastically  significant [p<0.05] 
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PROFORMA  
Name  
Age/Sex 
Address 
Occupation  
Chief complaints 
H/o smoking, alcohol, diabetes, hypertension,  
Family history of diabetes 
CLINICAL EXAMINATION 
General examination 
Routine investigations: 
Diabetic profile, Fasting lipid profile 
Investigations: 
Hba1c and C-reactive protein. 
 
  
MASTER CHART  
 
S.NO    NAME 
      
AGE     SEX    SHT 
        AT     
BASELINE  
     AFTER 6 
MONTHS 
          
       
HBA1C 
      
HSCRP 
      
HBA1C 
      
HSCRP 
1  ARRUKKANIAMMAL 72 F Y 9.1 10.51 8.5 9.45 
2  SELVANAYAGAM.P 51 M Y 10.43 0.62 8.11 0.41 
3  PONNUSAMY.M 62 M Y 12.8 4.01 9.02 2.08 
4 KRISHNAMANICKAM 65 M Y 12.11 0.98 9.85 0.88 
5  CHANDRA.K 44 F Y 10.7 4.2 7.03 2.02 
6  RAJATHI N 58 F Y 8.35 24.14 11.2 0.37 
7  PANDIYAN.M 55 M Y 10.94 1.29 7.3 0.46 
8  CHINNAMMAL 68 F Y 11.67 18.65 8.08 6.8 
9  MOHMAD GANI 56 M Y 9.68 0.05 6.4 0.02 
10  KANNAMAL 56 F Y 11.12 3.73 13 0.7 
11 VASUDEVAN.S 62 M Y 10.77 0.18 7.82 2.01 
12  RATHINAMBAL 70 F Y 9.39 0.9 8.09 2.5 
13 VENKATACHALAM 72 M Y 11.43 15.7 9.7 0.23 
14 MURUGATHAL.S 65 F Y 9.39 4.47 6.2 9.97 
15 QUEENI 61 F Y 11.8 32 8.8 13.5 
16 PARVATHI 70 F Y 9.45 0.25 
  17  RAJA.R 40 M Y 11.51 20.72 8.02 6.08 
18 ANNAPOORNI 52 F Y 8.84 0.7 7.02 0.4 
19 RAMAMOORTHY 49 M Y 8.19 0.85 6.89 0.5 
20 INDRANI 60 F Y 11.1 2.94 13.01 8.8 
21 BATHRAPPAN.C 58 M Y 10.3 16.79 7.8 8.05 
22  SUBBULAKSHMI 69 F Y 9.04 0.28 
  23  DAISY RANI 45 F Y 10.44 27.56 8.8 12.4 
24  MICHAEL.S 50 M Y 11.7 6.58 8.4 3.5 
25  SAKTHIVEL.R 59 M Y 9.3 23.48 9.1 20.4 
26  VIJAYA.B 48 F Y 8.41 1.55 6.4 0.5 
27 SUSAIMARY 62 F Y 9.14 0.76 
  28 SHAMNUGAM.P 61 M Y 14.9 13.12 6.2 9.92 
29  BAGYALAKSHMI 55 F Y 11.3 0.08 
  30 SUBBULAKSHMI.M 66 F Y 8.81 0.05 
  
 
 
